Author:
Todeschini P,Cocco E,Bellone S,Varughese J,Lin K,Carrara L,Guzzo F,Buza N,Hui P,Silasi D-A,Ratner E,Azodi M,Schwartz P E,Rutherford T J,Pecorelli S,Santin A D
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Alper O, Yamaguchi K, Hitomi J, Honda S, Matsushima T, Abe K (1990) The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. Cell Growth Differ 1: 591–599
2. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J (2006) Biosynthesis of tumourigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25: 3234–3244
3. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–2171
4. Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF (2004) Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res 24: 1083–1089
5. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC (1997) Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 73: 875–879
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献